Kornimate/medical-research-clean huggingface dataset:
oral health for healthy cognitive aging

Conditions: Malocclusion; Dementia

Summary: oral health is a critical factor of systemic health, although usually forgotten. a potential relation between cognitive deficits and oral diseases has been suggested. adult cognitive dysfunctions have a high impact, not only economic, but social and in the family environment. based on anatomical connectivity between the oral cavity and the central nervous system, the proposed study hypothesizes that masticatory function is a relevant determinant of human cognitive health. the restoration of canonical masticatory function and masticatory training could help to delay the development of such conditions. this project will also test if restoring phasic masticatory function improves the execution of cognitive tasks.

objective 1: to determine volumetric and anatomical changes of subcortical structures and cortical areas involved in the masticatory circuit and superior cognitive functions. objective 2: to determine the functional and brain connectivity changes associated with malocclusion and oral health. objective 3: to correlate the anatomic and functional changes associated with malocclusion and oral health with the performance of cognitive tasks representative of those executed in daily life.

Eligibility criteria:
inclusion criteria: * for dental occlusion restoration groups: need of, at least, two molar teeth replacement in the same quadrant. * for orthodontic treatment of malocclusion groups: class i, ii or iii malocclusion. exclusion criteria: * psychoactive drug. * central nervous system depressor. * patients not willing or not able to consent.

Keywords: dental occlusion oral health mastication dementia psychological health
comparative study of postieror ankle fracture

Conditions: Postieror Malleolar Fracture; Treatment

Summary: to compare the clinical efficacy of open reduction and internal fixation (orif) with plate and screw for postieror malleolar fractures.


Eligibility criteria:
inclusion criteria: supination-external rotation ⅳ type injury exclusion criteria: pion fracture; isolated posterior ankle fracture.
palliative primary tumor resection in minimally symptomatic patients with colorectal cancer and synchronous unresectable metastases

Conditions: Colorectal Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Neoplasms, Second Primary; Neoplasm Metastasis; Digestive System Diseases; Gastrointestinal Diseases; Colonic Disease; Intestinal Diseases; Rectal Diseases

Summary: currently, the question remains whether palliative primary tumor resection could improve overall survival of minimally symptomatic patients with colorectal cancer and synchronous unresectable metastases. the aim of this study is to determine if there is an improvement in overall survival of palliative primary tumor resection followed by chemotherapy in minimally symptomatic patients with colorectal cancer and synchronous unresectable metastases compared to those of upfront chemotherapy/radiotherapy alone.

the present study is a single-center retrospective observational cohort study with a propensity score matching. between 2016 and 2022 from our institutional database minimally symptomatic patients with colorectal cancer and synchronous unresectable metastases will be selected. patients will be divided into two groups: 1. surgical resection of the primary tumour before to systemic therapy 2. systemic therapy without previous resection of the primary tumour. propensity score matching (psm) will be performed, to minimize the selection bias by adjusting variables that may affect the survival of patients. categorical variables will be compared using the chi-square test or fisher's exact test. continuous variables will be compared using the student's t-test or mann-whitney u test. survival rate will be determined by using kaplan-meier analysis with a log-rank test. univariate and multivariate analyses for survival will be conducted using cox proportional hazard models. statistical results will be considered significant at p values less than 0.05.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed colorectal adenocarcinoma 2. resectable minimally symptomatic primary tumor with unresectable synchronous metastasis 3. age ≥ 18 years 4. informed consent exclusion criteria: 1. synchronous cancers 2. carcinomatosis 3. prior surgery, chemotherapy, radiation therapy for the primary tumor or distant metastases

Keywords: colorectal cancer primary tumor resection minimally symptomatic primary tumor unresectable metastases chemotherapy
switch of budesonide-formoterol dry powder inhalers at pharmacy in norway

Conditions: Asthma; COPD

Summary: this is a retrospective, multicentre, non-interventional, observational study in patients with asthma and/or copd who are treated with budesonide-formoterol.

in july 2018 norwegian authorities decided to allow switch at pharmacy for dry powder inhalers (dpis) containing budesonide-formoterol. pharmacists are instructed to switch patients to the inhaler with the lowest price. the pharmacist will train the patient on how to use the new inhaler. all patients whose eligible inhaler switch occurred between 1st july 2018 and 1st march 2019 will be eligible for the study.

Eligibility criteria:
inclusion criteria: 1. written informed consent has been obtained. 2. male or female patients with a diagnosis of asthma and/or copd whose budesonide-formoterol dpi was switched to another budesonide-formoterol dpi at pharmacy between 1st july 2018 and 1st march 2019 (referred to as the eligible switch). 3. age ≥12 years at time of switch. 4. treated with budesonide-formoterol for at least 12 months before the eligible switch (pre-switch period) and 12 months after the eligible switch (post-switch period). re-switch(es) of inhaler are allowed during the post-switch period. exclusion criteria: 1. patient has declined participation in the study or failed to respond to the invitation to participate.
alberta hip and knee replacement project

Conditions: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee

Summary: the study aims to determine if a new arthroplasty care model, established on evidence-based medicine and best practices, will improve patient outcomes and improve cost effectiveness for patients with severe degenerative joint disease of the hip or knee in alberta

the alberta orthopaedic society through its arthroplasty service design working group has, after carefully reviewing the existing conventional approach to arthroplasty care, developed what they believe could be a much improved new evidence based arthroplasty care model. this model represents how ideally a patient would access and receive health services across the complete continuum of care. in addition, wherever possible, evidence gathered from the literature and from "known best practices" has been utilized to develop standards related to access, wait times, clinical quality, resource use and health outcome measures. where no evidence or "known best practices" exist, a standard that best support achieving other known standards are being developed. this new evidence based arthroplasty model seeks to significantly minimize and where possible, eliminate all the current gaps and barriers to arthroplasty care. this study will seek to prove that the new evidence based arthroplasty model will deliver improved patient outcomes with improved cost effectiveness. once proven, it is anticipated that this new evidence based arthroplasty model will become the standard of care in alberta, and a model for other jurisdictions to use in their health service re-designs

Eligibility criteria:
inclusion criteria: * patient is at least 18 years of age * patient is able to provide written consent exclusion criteria: * patient has previously undergone arthroplasty of the same hip or knee (revision) * patient has a surgical date scheduled for arthroplasty * patient requires a hip resurfacing procedure or an oxford knee * patient has a concurrent medical condition that would contraindicate the patients' ability to participate fully in the study procedures, including terminal conditions such as chronic obstructive pulmonary disease, end stage renal disease, heart failure, malignancy with an anticipated life expectancy of ≤ 2 years * patient has senile dementia or alzheimer's disease

Keywords: arthroplasty health services research intent to treat randomized controlled
conservative treatment of ingrown toenail

Conditions: Ingrown Nail; Nails, Abnormal

Summary: ingrown toenail has become one of the most prevalent onychopathies and a frequent reason for consultation in podiatry clinics. in the initial stages of the pathology, conservative treatments are the first choice of therapy. the aim was therefore, to analyze and compare the efficacy of the technique of nail re-education with gauze bandage and nail remodelling for the conservative treatment of onychocryptosis in stage i and iia, a prospective, longitudinal, randomised clinical trial-type analytical study is proposed. a sample of 20 subjects with stage i and iia onychocryptosis will be selected. of these, 10 cases were part of the gauze bandage nail re-education group and the remaining 10 cases were part of the nail remodelling group.


Eligibility criteria:
inclusion criteria: * ingrown toenail in stage i or iia (mozena classification) exclusion criteria: * patients not allowed for clinical follow-up of the evolution of the pathology. * patients presented with deforming pathologies * pattens had been surgically operated for ingrown toenail

Keywords: ingrown toenail conservative treatment recurrence podiatry nail remodelling
study of the safety and efficacy of the human anti-tnf monoclonal antibody adalimumab in subjects with moderately to severely active psoriatic arthritis

Conditions: Arthritis; Psoriatic

Summary: multicenter study of the safety and efficacy of the human anti-tnf monoclonal antibody adalimumab in subjects with moderately to severely active psoriatic arthritis


Eligibility criteria:
inclusion criteria: * moderate to severe psa * inadequate response to dmard therapy * corticosteroid stable dose \<= 10 mg qd * dmards must have been taken for 3 months and stable dose for 4 weeks * mtx maximum dose = \<= 30 mg/week * active chronic plaque ps or documented history of chronic plaque ps exclusion criteria: * no other active skin disease
use of toric intraocular lens to neutralize keratometric astigmatism

Conditions: Cataract; Astigmatism

Summary: the purpose of this study is to evaluate neutralization of keratometric astigmatism in patients with cataract and astigmatism higher than 1 diopter, with phaco surgery and the implantation of a toric intraocular lens.

patients with cataract are treated with phacoemulsification of the lens with an implantation of an intraocular lens. besides cataract, almost 25% of these patients have some degree of astigmatism; when it is higher than 1 diopter, it is possible to neutralize it with an implantation of a toric intraocular lens.

Eligibility criteria:
inclusion criteria: * symmetrical keratometric astigmatism ≥ 1.0 d and cataract. exclusion criteria: * irregular astigmatism, * keratoconus, * previous refractive surgery.

Keywords: astigmatism cataract
efficacy and safety of dwj1252 in the treatment of functional dyspepsia

Conditions: Functional Dyspepsia

Summary: the purpose of this study is to evaluate the efficacy and safety of dwj1252 in treatment of functional dyspepsia.


Eligibility criteria:
inclusion criteria: * male of female of at least 19 years old * patient with functional dyspepsia met the rome iii criteria exclusion criteria: * patients with previous gastrointestinal surgery * patients with history of gastrointestinal bleeding, mechanical obstruction, perforation * patients with history of gastrointestinal cancer
marathon, genetics, inflammation and the cardiovascular system: magic-trial

Conditions: Heart Failure; Sudden Cardiac Death

Summary: the purpose of the study is to determine the myocardial function and vascular adaptation after strenuous exercise in association with genotype/polymorphisms. we aim to investigate the effects of extreme endurance exercise on the cardiovascular system. furthermore, the role of the inflammatory response and adaptive mechanisms of the vasculature are examined. subclinical injuries to the myocardium and vascular wall are being investigated.

regular exercise leads to an improvement of cardiovascular risc factors in patients with coronary heart disease, atherosclerosis and metabolic disorders. aerobic exercise has anti-inflammatory effects. in contrast, the exertional exercise of marathon running causes an acute pro-inflammatory impulse. this may lead to myocardial injury and, in case of preexisting plaques, may result in plaque rupture and acute myocardial infarction. we aim to define the critical role of inflammatory markers and cardiovascular risc factors as a predictor of an increased risk for myocardial and endothelial dysfunction in marathon runners. diagnostic tools include measurements of augmentation index (aix), arteriolar-venular ratio (avr) and, for the first time, 2d and 3d echocardiographic measurements such as tdi-imaging and speckle tracking. inflammatory markers include c-reactive protein (crp), interleukins and tumor necrosis factor. additionally, cardiovascular markers are measured. all variations are analysed on the basis of genotype characteristics/polymorphisms.

Eligibility criteria:
inclusion criteria: * men aged 30-60 years exclusion criteria: * manifested heart disease * insulin dependent diabetes mellitus * multi drug therapy * gfr\<60ml/min.

Keywords: exercise, myocardial dysfunction, endothelial dysfunction, polymorphism
a study of the efficacy and safety of antiwei granules in the treatment of common cold

Conditions: Common Cold

Summary: to further evaluate the efficacy and safety of antiwei granule in the treatment of common cold (wind-cold syndrome)


Eligibility criteria:
inclusion criteria: 1. it met the diagnostic criteria of common cold in western medicine; 2. in accordance with the tcm syndrome differentiation standard of wind-cold syndrome; 3. male and female patients aged 18 to 65 years; 4. the disease duration at enrollment was ≤48 h; 5. at enrollment, 37.3 ° c ≤axillary temperature \< 38.5 ° c; 6. informed consent was obtained voluntarily. exclusion criteria: 1. complicated with influenza, pneumonia, suppurative tonsillitis, acute tracheobronchitis, acute pharyngeal conjunctivitis, acute viral or herpetic pharyngitis, acute viral or herpetic laryngitis; 2. patients who had been infected with 2019-ncov in the past and still had symptoms such as cough and fatigue for nearly 3 months after the antigen turned negative; 3. primary ciliary dyskinesia syndrome, other acute onset nasal diseases (such as allergic rhinitis, chronic rhinitis, acute and chronic sinusitis, etc.), previous nasal surgery or radiotherapy of the nasopharynx with nasal mucosal dysfunction； 4. patients with chronic respiratory diseases (such as chronic obstructive pulmonary disease, interstitial lung disease, etc.), asthma, and tuberculosis; 5. white blood cell count \>12.0×10\^9/l or \ 80%; 6. aspartate aminotransferase and/or alanine aminotransferase ≥ 1.5 × uln, or serum creatinine ≥ uln, judged by the investigator to be clinically significant； 7. combined with other serious primary diseases of the heart, brain, lung, liver, kidney or blood system, such as unstable control/serious complications of diabetes, viral hepatitis, hemophilia, or mental disorders; 8. patients who had been treated with chinese and western drugs for the relief of common cold and its symptoms after the onset of the current illness, including but not limited to antibiotics, antiviral, antihistamine, steroids, decongestants, antipyretic and analgesic, antitussive and expectorant drugs etc; 9. those who were allergic to the known composition of the investigational drug or to emergency medication, or emergency drug contraindication population; 10. the participants (and their partners) had planned pregnancy or were unwilling to take appropriate contraceptive measures from enrollment to 1 month after the end of the trial, or were pregnant or lactating; 11. suspected or true history of alcohol or drug abuse; 12. participants who had participated in another clinical trial within 1 month before enrollment; 13. persons deemed unsuitable for clinical trial by the investigator (e.g., athletes or persons not eligible for enrollment for other reasons).
drug-coated balloon in native chronic total occlusion percutaneous coronary intervention

Conditions: Coronary Artery Disease; Total Occlusion of Coronary Artery

Summary: the imagination trial is an investigator-initiated, prospective, single-center study of symptomatic patients with a native chronic total occlusion (cto) undergoing intravascular ultrasound (ivus)-guided percutaneous coronary intervention (pci) with a drug-coated balloon (dcb). post-pci ivus and fractional flow reserve (ffr) at baseline and at 6-months follow-up will be performed. in addition, patients included in the coronary computed tomography angiography (ccta) substudy will undergo ccta at 12-months follow-up. the aim of this study is to evaluate the efficacy and safety of dcb-only approach in native coronary cto.

whereas cto pci techniques and success rates have significantly improved during the last decade, ctos still pose a significant technical challenge for accurate stent sizing (primarily due to negative remodelling and subsequent distal vessel dilatation post-pci) resulting in a potentially increased risk of stent failure. hence, the concept of dcb as a definitive treatment for native cto is appealing and warrants further investigation. the imagination trial has been designed as a prospective research to: 1) investigate both the immediate and intermediate-term angiographic, ivus and physiologic efficacy outcomes as well as safety profile of dcb for native vessel coronary cto, and 2) to provide a basis for future randomized clinical trial comparing dcb to drug-eluting stents. all patients with cto will be screened for potential inclusion in the study. after obtaining written informed consent, patients with successful intraplaque guidewire crossing through cto lesion (excluding the use of dissection and re-entry techniques) will undergo ivus-guided pci with a scoring balloon (balloon-to-artery ratio of 1:1) followed by the use of a paclitaxel-coated balloon. following satisfactory angiographic result, ivus and physiological measurements (ffr and non-hyperemic pressure ratios) in the target vessel will be performed. at 6-months follow-up, invasive angiography with ivus and ffr/non-hyperemic pressure ratios in the target vessel will be repeated. in addition, patients with pre-procedural ccta will undergo follow-up ccta after 12 months (ccta substudy).

Eligibility criteria:
inclusion criteria: * clinical indication for cto pci as determined by the local heart team (presence of angina or equivalent symptoms and/or documented ischemia or viability) * native cto lesion as defined by invasive coronary angiography * informed consent for participation in the study exclusion criteria: * \<18 years of age * myocardial infarction * cardiogenic shock * severe valvular disease * estimated life expectancy \<1 year * contraindication to pci * positive pregnancy test or breast-feeding * in-stent cto * cto recanalization using antegrade or retrograde dissection and re-entry techniques

Keywords: chronic total occlusion percutaneous coronary intervention drug-coated balloon
vircapseq virus detection in sézary syndrome

Conditions: Lymphoma, T-Cell, Cutaneous; Sézary Syndrome

Summary: this study will be using this technique, called "vircapseq-vert" to analyze the white blood cells of patients with sézary syndrome. this could provide the foundation for future studies looking to understand the role that viruses play in the origin of sézary syndrome. this could have important implications for the future development of new and effective therapies for the disease.

cutaneous t-cell lymphoma (ctcl) is a rare lymphoproliferative disorder characterized by malignant cd4+ t-cells that infiltrate the skin. while most cases are confined to skin, ctcl is also capable of affecting the blood, lymph nodes, and visceral organs. sézary syndrome (ss) is a leukemic variant of the disease with a poor prognosis and can arise with or without cutaneous involvement. the pathogenesis of ctcl is poorly understood, but chronic antigen stimulation possibly due to a bacterial or viral infection or colonization of the skin may lead to malignant transformation of the skin resident t cells. colonization of the skin of ctcl patients with staphylococcus aureus is common and can lead to the clonal expansion of malignant t cells in the skin. however, its role as an etiological agent is unlikely, considering commonality of s.aureus and rarity of the skin t-cell lymphomas. mounting evidence suggests that oncogenic viral pathogen may play a role, but all efforts to implicate certain viruses, such as retroviruses or herpesviruses have yielded inconsistent results. this study will use the most sensitive method to date, a novel viral detection technique capable of detecting every known vertebrate virus in tissue samples, called "virome capture sequencing platform for vertebrate viruses (vircapseq-vert)." this allows it to detect previously undiscovered viruses that diverge from known sequences by as much as 40%.

Eligibility criteria:
inclusion criteria: * patients with sézary syndrome diagnosed according to the who-eortc classification. exclusion criteria: * pregnant patients. * patients with known anemia with documented \<7.5 mg/dl. * patients who are unable to give informed consent.
3d versus 4k laparoscopic cholecystectomy

Conditions: Cholecystitis; Gallstones

Summary: introduction: three-dimensional key-hole surgery ('laparoscopic') systems are proven to reduce the time required to complete tasks in laboratory settings. this benefit derives from the addition of binocular depth perception cues when compared to two-dimensional (2d) systems. this year a '4k' laparoscopic system has become commercially available, so-named as it provides a high resolution 2d image with four times the number of pixels of 2d full high definition. the improved visualisation is likely to provide additional non-binocular depth cues. it is currently unclear to what degree improving the resolution of 2d systems can compensate for binocular depth cues. aim: to determine whether the binocular vision provided by 3d laparoscopic systems provides benefits during laparoscopic cholecystectomy when compared to the monocular vision provided by high-resolution 4k systems. methods: a randomised controlled trial of 3d hd versus 4k laparoscopic systems will be performed, comparing the time to complete laparoscopic cholecystectomy, and error scores. impact: this study is a unique, first-of-its-kind investigation into two new surgical technologies, and is the first study to involve a 4k system. the uptake of three-dimensional systems has been curbed by financial cost and the limitations of early 3d technologies. this study aims to determine which system may be the safest, quickest and most cost- effective, in order to guide future investment and technological development towards either 3d or 2d systems. in addition, these systems may also aid in the learning curve of trainee surgeons.


Eligibility criteria:
inclusion criteria: 1. informed, written consent obtained after provision of information leaflets and face-to-face answering of any questions participants may have 2. elective laparoscopic cholecystectomy 3. medically fit for discharge as day case 4. age 18 to 85 years exclusion criteria: 1. unable to obtain informed, written consent 2. emergency cholecystectomy 3. not medically fit for discharge as day case 4. age \ 85 years 5. conversion to open cholecystectomy 6. history of upper abdominal surgery 7. recent/current involvement in another clinical trial 8. common bile duct exploration at time of operation